Connect with us

Business

Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

Published

on

Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit


Merck on Thursday reported third-quarter earnings and revenue that topped estimates as it saw strong demand for its cancer immunotherapy Keytruda.

The drugmaker also narrowed its full-year profit outlook to reflect lower estimated tariff costs, among other factors. Shares of Merck closed flat on Thursday.

Sales of Keytruda topped $8 billion for the first time in a quarter, rising 10% from the same period a year ago. Revenue from the drug of $8.14 billion came in just slightly under the $8.24 billion analysts were expecting, according to StreetAccount estimates. 

The results come as Merck slashes $3 billion in costs by the end of 2027, and prepares to offset revenue losses from the upcoming patent expiration of Keytruda in 2028.

The pharmaceutical giant now expects its 2025 adjusted earnings to come in between $8.93 and $8.98 per share. That compares with its previous outlook of $8.87 to $8.97.

Merck said that reflects several new items, including “lower estimated costs related to the impact of tariffs.” During the previous two quarters, the company included a $200 million estimated hit from tariffs that President Donald Trump has implemented to date, but not his planned pharmaceutical-specific levies. Merck did not disclose a new estimate for the cost of existing tariffs. 

Merck said the guidance also reflects a benefit from an amended deal with AstraZeneca related to a pill for a specific genetic disorder, partially offset by costs tied to the company’s now-completed acquisition of Verona Pharma. 

Merck expects revenue for the year to come in between $64.5 billion and $65 billion, narrowed on both ends from its previous guidance of $64.3 billion to $65.3 billion. 

Here’s what Merck reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

  • Earnings per share: $2.58 adjusted vs. $2.35 expected
  • Revenue: $17.28 billion vs. $16.96 billion expected

The company posted net income of $5.79 billion, or $2.32 per share, for the quarter. That compares with net income of $3.16 billion, or $1.24 per share, for the year-earlier period. 

Excluding acquisition and restructuring costs, Merck earned $2.58 per share for the third quarter.

Merck raked in $17.28 billion in revenue for the quarter, up 4% from the same period a year ago.

Merck continued to see trouble with China sales of Gardasil, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S.

In February, Merck announced a decision to halt shipments of Gardasil into China beginning that month. In July, CFO Caroline Litchfield said the company will not resume shipments to China through at least the end of 2025, noting that inventories remain high and demand is still soft.

Gardasil generated sales of $1.75 billion for the quarter, down 24% from the same period a year ago due to lower demand in China. Still, that was in line with what analysts were expecting, according to StreetAccount.

Investors are eager for additional updates on Gardasil’s presence in China and any details from Merck on potential drug pricing deals with Trump as part of his controversial “most favored nation” policy. Trump has so far inked agreements with Pfizer, AstraZeneca and EMD Serono, the largest fertility drug manufacturer in the world, that aim to make their medicines easier for Americans to access.

In an earnings call on Thursday, Merck CEO Rob Davis said the company shares the Trump administration’s goal of “decreasing patient out-of-pocket costs for our products in the U.S. while at the same time realizing greater prices for our medicines and vaccines in countries that have not been paying fair value for the innovation we provide.” 

Merck is “actively engaged” with the administration to achieve those efforts. 

Pharmaceutical, animal health sales

Merck’s pharmaceutical unit, which develops a wide range of drugs, booked $15.61 billion in revenue during the third quarter. That’s up 4% from the same period a year earlier.

The increase in Keytruda was driven by higher uptake of the drug for earlier-stage cancers and strong demand for the treatment for metastatic cancers, which spread to other parts of the body, the company said.

Meanwhile, Merck’s newer drug Winrevair, which is used to treat a rare, deadly lung condition, recorded $360 million in sales for the quarter. Analysts had expected the medication to bring in $413 million, according to StreetAccount estimates. 

Winrevair’s growth largely reflects higher uptake in the U.S. But it was partially offset by the timing of distributor purchases of the drug and lower net pricing in the country, mainly due to changes to Medicare prescription drug plans. 

Merck’s animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted nearly $1.62 billion in sales, up 9% from the same period a year prior. The company said that mainly reflects higher demand for livestock products.

Correction: Sales for Merck’s animal health division were up 9% from the same period a year prior. An earlier version misstated the percentage.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

UK borrowing higher than expected in February

Published

on

UK borrowing higher than expected in February



The ONS said an increase in government tax receipts was outweighed by a rise in spending.



Source link

Continue Reading

Business

Iran oil attacks trigger 35% gas price spike – and fears of interest rate rises

Published

on

Iran oil attacks trigger 35% gas price spike – and fears of interest rate rises



Britain is to “step up” defensive support for Gulf states after Iran attacked energy sites across the region in a “serious escalation” of the war that could push up inflation and interest rates.

The price of Brent crude climbed as high as $119 a barrel and European gas prices briefly surged by 35 per cent after Iran pounded Qatar’s Ras Laffan energy hub and other Middle Eastern oil and gas infrastructure with missiles.

Interest rates were held at 3.75 per cent instead of the previously expected cut, as the Bank of England warned that the war could push inflation as high as 3.5 per cent by July on the back of rising energy bills, and that rates could rise – creating misery for homeowners.

It came as:

  • US defence secretary Pete Hegseth said “ungrateful” European allies should be thanking Donald Trump for the war
  • Trump claimed he was unaware of Israel’s strike on Iran’s South Pars gas field
  • Oman called the US/Israel attacks a “grave miscalculation”
  • Europe’s biggest airlines warned of higher fares

Iran’s attacks were in retaliation to an Israeli strike on the vital South Pars gas field, which drew condemnation from the Gulf states as well as Tehran. It was the first attack of the war so far on an energy production facility. Tehran fired missiles at multiple energy sites across the Gulf, including a Saudi oil refinery, Qatari gas facilities and two more oil refineries in Kuwait.

While Sir Keir Starmer and Emmanuel Macron called for de-escalation, President Trump threatened to “massively blow up” the South Pars facility if Iran did not halt its retaliatory attacks, repeating his claim that US forces had “obliterated” Iran’s navy and military, adding that the war was “substantially ahead of schedule”. He denied that plans were being made to send more American troops to the region.

John Healey, the UK defence secretary, said Tehran’s tit-for-tat responses threatened to further destabilise the region and Europe’s economies. He called them a “serious escalation”, adding: “They further destabilise the region and we will step up the defensive support that we can offer to those Gulf states.”

British forces are already deployed to the Middle East, with RAF jets flying defensive sorties against Iranian drones across the Gulf and British air defence systems protecting critical infrastructure in Saudi Arabia. UK military planners have also joined US Central Command to help formulate proposals for opening the Strait of Hormuz, a critical trade route for the world’s oil and gas.But there were signs of growing frustration towards Washington’s war aims in the Gulf states, with Oman’s foreign minister claiming that the conflict was President Trump’s “greatest miscalculation”.

In the most scathing attack on Washington’s foreign policy yet by a Gulf state, Badr Albusaidi said “this is not America’s war” and criticised Mr Trump for supporting Israel. Writing in The Economist, he called on American allies to help extricate it from the conflict, which has continued for a third week despite failing to achieve the US and Israel’s stated aim of instigating regime change in Tehran or stopping its nuclear programme.

Meanwhile, the Bank of England has warned that it may have to put up interest rates if the war continues to drive up inflation and unemployment. Its governor, Andrew Bailey, said the impact was already being felt by consumers as petrol prices surge and that he is “ready to act as necessary to ensure inflation remains on track to meet the 2 per cent target”. That would pave the way for a rate hike as early as the end of April.

Bets on the financial markets suggest a 50/50 chance that Britain will face higher interest rates from next month – and the possibility of two more rises by the end of the year.

Danni Hewson, head of financial analysis at AJ Bell, said: “Markets are now pricing in an almost 50 per cent chance that April’s meeting will see rates rise to 4 per cent with the potential for two additional rate hikes by the end of the year. But no one has a crystal ball. No one knows how long the conflict will last or the amount of damage that could be inflicted on crucial energy infrastructure by the time it ends.”



Source link

Continue Reading

Business

Stock market today (March 20, 2026): Nifty50 opens above 23,200; BSE Sensex up over 700 points – The Times of India

Published

on

Stock market today (March 20, 2026): Nifty50 opens above 23,200; BSE Sensex up over 700 points – The Times of India


Stock market today (AI image)

Stock market today: Benchmark indices Nifty50 and BSE Sensex opened in green on Friday after a big selloff on Thursday that saw markets tank over 3%. While Nifty50 opened above 23,200, BSE Sensex rose over 700 points, just shy of 75,000. At 9:16 AM, Nifty50 was trading at 23,229.15, up 227 points or 0.99%. BSE Sensex was at 74,945.45, up 738 points or 0.99%.Dr. VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited says, “Market has been oscillating between some hope and fear during the last four days. The gains which Nifty accumulated in the previous three days have been completely wiped out with the 775 point loss yesterday. This oscillation between hope and fear is likely to continue in the near-term.Today there is potential for the market to move up since hope of de-escalation is back. Israel PM’s remarks yesterday indicate that there won’t be further attacks on Iran’s oil and gas infrastructure. This has cooled the Brent crude to $ 106 from the peak of $118 yesterday. The HDFC issue impacted Nifty Bank significantly yesterday and it also contributed to the crash in Nifty. This is likely to be a storm in a tea cup. Even though the uncertainty continues, the market construct is ripe for a bounce back today. Beaten down financials and autos are set for a bounce back.”Indian equity markets tumbled sharply on Thursday, breaking a three-day gaining streak, as escalating tensions in West Asia sparked a global risk-off sentiment. Analysts said the market is entering a phase of heightened vulnerability, with investor confidence increasingly influenced by fast-moving geopolitical developments and a surge in crude oil prices.Asian markets opened higher on Friday after US equities recovered from their intraday lows and oil prices eased. However, Wall Street had closed lower on Thursday, dragged down by declines in Micron Technology and Tesla, as rising oil prices stoked inflation worries and dampened expectations of future interest rate cuts.Gold prices edged up on Friday but were still set for a third straight weekly decline, pressured by a strong dollar and the US Federal Reserve’s hawkish stance, which has reduced hopes of near-term monetary easing. Oil prices, meanwhile, fell on Friday after major European countries and Japan signalled their willingness to support measures to ensure safe passage for vessels through the Strait of Hormuz, while the US outlined steps to boost supply.Foreign portfolio investors remained net sellers, offloading equities worth Rs 7,558 crore on Thursday, while domestic institutional investors provided some support, purchasing shares worth Rs 3,864 crore.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)



Source link

Continue Reading

Trending